Clinical Trial Update: An Interventional Study of Infigratinib in Children With Hypochondroplasia [Phase 2, Phase 3]

View source ↗

Summary

Interventional Phase 2/3 study of Infigratinib in children with hypochondroplasia is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypochondroplasia

Drugs mentioned

• Infigratinib (infigratinib)

Snippet

Sponsor: QED Therapeutics, a BridgeBio company | Conditions: Hypochondroplasia | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION